| Code | CSB-RA004936MB18HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Ravagalimab, targeting CD40, a critical costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. CD40 is expressed on antigen-presenting cells, B lymphocytes, and various non-immune cells, where it plays a pivotal role in adaptive immunity by regulating B cell activation, immunoglobulin class switching, and T cell priming. Dysregulation of CD40 signaling has been implicated in autoimmune disorders, inflammatory conditions, and cancer, making it an important therapeutic target for immune modulation.
Ravagalimab is an investigational agonistic anti-CD40 antibody initially developed for cancer immunotherapy, designed to enhance antitumor immunity by activating dendritic cells and promoting T cell responses. This biosimilar antibody provides researchers with a valuable tool for investigating CD40-mediated immune mechanisms, exploring combination immunotherapy strategies, and studying the receptor's role in tumor microenvironment modulation and autoimmune disease pathogenesis. It enables cost-effective research into CD40 pathway biology and supports preclinical validation studies.
There are currently no reviews for this product.